Difficulties in treatment and management of epilepsy and challenges in new drug development

Pharmaceuticals

Volumn 3, Issue 7, 2010, Pages 2090-2110

  Wahab, Abdul ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Anticonvulsant; Antiepileptic; Pharmacoresistance; Refractory seizures; Seizure

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BROMINE DERIVATIVE; CARBAMAZEPINE; CLOBAZAM; DIAZEPAM; ETHOSUXIMIDE; ETHYL(PHENYL)MALONAMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PENTETRAZOLE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; RUFINAMIDE; STIRIPENTOL; THYPHENYTOIN; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABDOMINAL PAIN; ACUTE DISEASE; AGRANULOCYTOSIS; ALCOHOL WITHDRAWAL; ANOREXIA; ANXIETY DISORDER; APLASTIC ANEMIA; ASTHENIA; ATAXIA; BEHAVIOR DISORDER; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BLINDNESS; BLURRED VISION; CLEFT LIP FACE PALATE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COARSE FACE; COGNITIVE DEFECT; COMPLEX PARTIAL SEIZURE; CONGENITAL HEART MALFORMATION; DEPRESSION; DEVELOPMENTAL DISORDER; DIARRHEA; DIPLOPIA; DISTRACTIBILITY; DIZZINESS; DROWSINESS; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DUPUYTREN CONTRACTURE; DYSARTHRIA; DYSPEPSIA; EMOTIONAL DISORDER; EPILEPSY; EPILEPTIC STATE; ESSENTIAL TREMOR; FATIGUE; FETUS MALFORMATION; FEVER; FOCAL EPILEPSY; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GRAND MAL SEIZURE; GROUPS BY AGE; GROWTH RETARDATION; HAIR LOSS; HEADACHE; HEPATITIS; HIRSUTISM; HUMAN; HYPERACTIVITY; HYPERKINESIA; HYPERSALIVATION; HYPONATREMIA; INCIDENCE; INFANTILE SPASM; INSOMNIA; IRRITABILITY; KETOGENIC DIET; LENNOX GASTAUT SYNDROME; LETHARGY; LEUKOPENIA; LIBIDO DISORDER; LIVER NECROSIS; LIVER TOXICITY; MENTAL DISEASE; MICROCEPHALY; MIGRAINE; MOOD CHANGE; MYOCLONUS EPILEPSY; NAUSEA; NEPHROLITHIASIS; NERVOUSNESS; NEURAL TUBE DEFECT; NEUROPATHIC PAIN; NONHUMAN; NYSTAGMUS; OSTEOMALACIA; OVARY POLYCYSTIC DISEASE; PANCREATITIS; PARESTHESIA; PERIPHERAL EDEMA; PETIT MAL; POSTHERPETIC NEURALGIA; PSYCHOSIS; RASH; RESTLESS LEGS SYNDROME; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TERATOGENICITY; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE; TREMOR; TRIGEMINUS NEURALGIA; UNSPECIFIED SIDE EFFECT; VERTIGO; VISUAL DISORDER; VISUAL FIELD DEFECT; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 77955676943     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3072090     Document Type: Review

References (187)

1. Elferink, J. G. Epilepsy and its treatment in the ancient cultures of America. Epilepsia 1999, 40, 1041-1046.
2. Satishchandra, P.; Gururaj, G.; Mohammed, Q. D.; Senanayake, N.; Silpakit, O. From Prejudice to Hope. Global Campaign against Epilepsy: Out of the Shadows; World Health Organization: Geneva, Switzerland, 2001; pp. 6-9.
3. Jackson, J. H. On the anatomical, physiological and pathological investigation of epilepsies. West Riding Lunatic Asylum Medical Reports 1873, 3, 315-339.
4. Penfield, W.; Jasper, H. Epilepsy and the Functional Anatomy of the Human Brain; Little, Brown and Company: Boston, MA, USA, 1954; pp. 3-40.
5. McNamara, J. O. Emerging insights into the genesis of epilepsy. Nature 1999, 399, A15-A22.
6. Noebels, J. L. The biology of epilepsy genes. Annu. Rev. Neurosci. 2003, 26, 599-625.
7. Duncan, J. S. Brain imaging in idiopathic generalized epilepsies. Epilepsia 2005, 46 (Suppl. 9), 108-111.
8. Bazil, C. W.; Pedley, T. A. Advances in the medical treatment of epilepsy. Annu. Rev. Med. 1998, 49, 135-162.
9. McCabe, P. H. New anti-epileptic drugs for the 21st century. Expert. Opin. Pharmacother. 2000, 1, 633-674.
10. Perucca, E.; French, J.; Bialer, M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 2007, 6, 793-804.
11. Johannessen, L. C.; Patsalos, P. N. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert. Rev. Neurother. 2010, 10, 119-140.
12. Heinemann, U.; Draguhn, A.; Ficker, E.; Stabel, J.; Zhang, C. L. Strategies for the development of drugs for pharmacoresistant epilepsies. Epilepsia 1994, 35 (Suppl. 5), S10-S21.
13. Kupferberg, H. Animal models used in the screening of antiepileptic drugs. Epilepsia 2001, 42 (Suppl. 4), 7-12.
14. Holmes, G. L.; Zhao, Q. Choosing the correct antiepileptic drugs: from animal studies to the clinic. Pediatr. Neurol. 2008, 38, 151-162.
15. Bialer, M.; White, H. S. Key factors in the discovery and development of new antiepileptic drugs. Nat. Rev. Drug Discov. 2010, 9, 68-82.
16. Sander, J. W.; Shorvon, S. D. Epidemiology of the epilepsies. J. Neurol. Neurosurg. Psychiatry 1996, 61, 433-443.
17. Brodie, M. J.; Shorvon, S. D.; Canger, R.; Halasz, P.; Johannessen, S.; Thompson, P.; Wieser, H. G.; Wolf, P. Commission on European affairs: appropriate standards of epilepsy care across Europe. ILEA. Epilepsia 1997, 38, 1245-1250.
18. Banerjee, P. N.; Filippi, D.; Allen, H. W. The descriptive epidemiology of epilepsy - A Review. Epilepsy Res. 2009, 85, 31-45.
19. Bell, G. S.; Sander, J. W. The epidemiology of epilepsy: the size of the problem. Seizure 2001, 10, 306-314.
20. Scott, R. A.; Lhatoo, S. D.; Sander, J. W. The treatment of epilepsy in developing countries: where do we go from here? Bull. World Health Organ. 2001, 79, 344-351.
21. Meinardi, H.; Scott, R. A.; Reis, R.; Sander, J. W. The treatment gap in epilepsy: the current situation and ways forward. Epilepsia 2001, 42, 136-149.
22. Mbuba, C. K.; Ngugi, A. K.; Newton, C. R.; Carter, J. A. The epilepsy treatment gap in developing countries: a systematic review of the magnitude, causes, and intervention strategies. Epilepsia 2008, 49, 1491-1503.
23. Radhakrishnan, K. Challenges in the management of epilepsy in resource-poor countries. Nat. Rev. Neurol. 2009, 5, 323-330.
24. Senanayake, N.; Roman, G. C. Epidemiology of epilepsy in developing countries. Bull. World Health Organ. 1993, 71, 247-258.
25. Arida, R. M.; Scorza, C. A.; Schmidt, B.; de Albuquerque, M.; Cavalheiro, E. A.; Scorza, F. A. Physical activity in sudden unexpected death in epilepsy: much more than a simple sport. Neurosci. Bull. 2008, 24, 374-380.
26. Johnston, A.; Smith, P. Sudden unexpected death in epilepsy. Expert. Rev. Neurother. 2007, 7, 1751-1761.
27. Tomson, T.; Nashef, L.; Ryvlin, P. Sudden unexpected death in epilepsy: current knowledge and future directions. Lancet Neurol. 2008, 7, 1021-1031.
28. Leestma, J. E.; Walczak, T.; Hughes, J. R.; Kalelkar, M. B.; Teas, S. S. A prospective study on sudden unexpected death in epilepsy. Ann. Neurol. 1989, 26, 195-203.
29. Langan, Y. Sudden unexpected death in epilepsy (SUDEP): risk factors and case control studies. Seizure. 2000, 9, 179-183.
30. Tomson, T.; Walczak, T.; Sillanpaa, M.; Sander, J. W. Sudden unexpected death in epilepsy: a review of incidence and risk factors. Epilepsia 2005, 46 (Suppl. 11), 54-61.
31. Sander, J. W.; Hart, Y. M.; Johnson, A. L.; Shorvon, S. D. National general practice study of epilepsy: newly diagnosed epileptic seizures in a general population. Lancet 1990, 336, 1267-1271.
32. Coppola, A.; Moshe, S. L. Why is the developing brain more susceptible to status epilepticus? Epilepsia 2009, 50 (Suppl. 12), 25-26.
33. Wahab, A.; Albus, K.; Heinemann, U. Age and region specific effects of anticonvulsants and bumetanide on 4-aminopyridine induced seizure like events in hippocampal-entorhinal cortex slices. Epilepsia, 2010, accepted.
34. Usta, I. M.; Adra, A. M.; Nassar, A. H. Ultrasonographic diagnosis of fetal seizures: a case report and review of the literature. BJOG. 2007, 114, 1031-1033.
35. Sheizaf, B.; Mazor, M.; Landau, D.; Burstein, E.; Bashiri, A.; Hershkovitz, R. Early sonographic prenatal diagnosis of seizures. Ultrasound Obstet. Gynecol. 2007, 30, 1007-1009.
36. Sun, Y.; Vestergaard, M.; Pedersen, C. B.; Christensen, J.; Basso, O.; Olsen, J. Gestational age, birth weight, intrauterine growth, and the risk of epilepsy. Am. J. Epidemiol. 2008, 167, 262-270.
37. Vestergaard, M.; Basso, O.; Henriksen, T. B.; Ostergaard, J. R.; Olsen, J. Risk factors for febrile convulsions. Epidemiology 2002, 13, 282-287.
38. Albala, B. J.; Moshe, S. L.; Okada, R. Kainic-acid-induced seizures: a developmental study. Brain Res. 1984, 315, 139-148.
39. Sperber, E. F.; Haas, K. Z.; Stanton, P. K.; Moshe, S. L. Resistance of the immature hippocampus to seizure-induced synaptic reorganization. Brain Res. Dev. Brain Res. 1991, 60, 88-93.
40. Stafstrom, C. E.; Thompson, J. L.; Holmes, G. L. Kainic acid seizures in the developing brain: status epilepticus and spontaneous recurrent seizures. Brain Res. Dev. Brain Res. 1992, 65, 227-236.
41. Baram, T. Z.; Eghbal-Ahmadi, M.; Bender, R. A. Is neuronal death required for seizure-induced epileptogenesis in the immature brain? Prog. Brain Res. 2002, 135, 365-375.
42. Riviello, P.; de, R. L., I; Holmes, G. L. Lack of cell loss following recurrent neonatal seizures. Brain Res. Dev. Brain Res. 2002, 135, 101-104.
43. Raol, Y. S.; Budreck, E. C.; Brooks-Kayal, A. R. Epilepsy after early-life seizures can be independent of hippocampal injury. Ann. Neurol. 2003, 53, 503-511.
44. Dube, C.; Richichi, C.; Bender, R. A.; Chung, G.; Litt, B.; Baram, T. Z. Temporal lobe epilepsy after experimental prolonged febrile seizures: prospective analysis. Brain 2006, 129, 911-922.
45. Holmes, G. L. Effects of seizures on brain development: lessons from the laboratory. Pediatr. Neurol. 2005, 33, 1-11.
46. Kramer, G. Epilepsy in the elderly: some clinical and pharmacotherapeutic aspects. Epilepsia 2001, 42 (Suppl. 3), 55-59.
47. Bergey, G. K. Initial treatment of epilepsy: special issues in treating the elderly. Neurology 2004, 63, S40-S48.
48. Regesta, G.; Tanganelli, P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res. 1999, 34, 109-122.
49. French, J. A. Refractory epilepsy: clinical overview. Epilepsia 2007, 48 (Suppl. 1), 3-7.
50. Leppik, I. E. Intractable epilepsy in adults. Epilepsy Res. (Suppl.) 1992, 5, 7-11.
51. Spencer, S. S. When should temporal-lobe epilepsy be treated surgically? Lancet Neurol. 2002, 1, 375-382.
52. Arts, W. F.; Brouwer, O. F.; Peters, A. C.; Stroink, H.; Peeters, E. A.; Schmitz, P. I.; van Donselaar, C. A.; Geerts, A. T. Course and prognosis of childhood epilepsy: 5-year follow-up of the Dutch study of epilepsy in childhood. Brain 2004, 127, 1774-1784.
53. Wahab, A.; Albus, K.; Gabriel, S.; Heinemann, U. In search for models of pharmacoresistant epilepsy. A review. Epilepsia 2010, 51 (Suppl. 3), 154-159.
54. Berg, A. T.; Shinnar, S. Relapse following discontinuation of antiepileptic drugs: a meta-analysis. Neurology 1994, 44, 601-608.
55. Specchio, L. M.; Tramacere, L.; La Neve, A.; Beghi, E. Discontinuing antiepileptic drugs in patients who are seizure free on monotherapy. J. Neurol. Neurosurg. Psychiatry 2002, 72, 22-25.
56. Musicco, M.; Beghi, E.; Solari, A.; Viani, F. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. First seizure trial group (FIRST Group). Neurology 1997, 49, 991-998.
57. Berg, A. T.; Langfitt, J.; Shinnar, S.; Vickrey, B. G.; Sperling, M. R.; Walczak, T.; Bazil, C.; Pacia, S. V.; Spencer, S. S. How long does it take for partial epilepsy to become intractable? Neurology 2003, 60, 186-190.
58. Devinsky, O. Patients with refractory seizures. N. Engl. J. Med. 1999, 340, 1565-1570.
59. Arroyo, S.; Brodie, M. J.; Avanzini, G.; Baumgartner, C.; Chiron, C.; Dulac, O.; French, J. A.; Serratosa, J. M. Is refractory epilepsy preventable? Epilepsia 2002, 43, 437-444.
60. Schuele, S. U.; Luders, H. O. Intractable epilepsy: management and therapeutic alternatives. Lancet Neurol. 2008, 7, 514-524.
61. Heinemann, U. Basic mechanisms of partial epilepsies. Curr. Opin. Neurol. 2004, 17, 155-159.
62. Schmidt, D.; Loscher, W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005, 46, 858-877.
63. Remy, S.; Beck, H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 2006, 129, 18-35.
64. Raza, M.; Choudhary, M. I.; Atta-ur-Rahman. Medicinal plants with anticonvulsant activities. In Studies in Natural Product Chemistry; Atta-ur-Rahman, Ed.; Elsevier Science Publishers: Amsterdam, The Netherlands, 2000; Volume 22, pp. 507-553.
65. Schachter, S. C. Botanicals and herbs: a traditional approach to treating epilepsy. Neurotherapeutics 2009, 6, 415-420.
66. Krall, R. L.; Penry, J. K.; Kupferberg, H. J.; Swinyard, E. A. Antiepileptic drug development: i. History and a program for progress. Epilepsia 1978, 19, 393-408.
67. Shorvon, S. D. Drug treatment of epilepsy in the century of the ILAE: the first 50 years, 1909-1958. Epilepsia 2009, 50 (Suppl. 3), 69-92.
68. Hauptmann, A. Luminal bei epilepsie. Münchener Medizinische Wochenschrift 1912, 59, 1907-1909.
69. Wilder, R. M. Effects of ketonuria on the course of epilepsy. Mayo Clin. Bull. 1921, 2, 307-314.
70. Lennox, W. G. Ketogenic diet in the treatment of epilepsy. N. Engl. J. Med. 1928, 199, 74-75.
71. Wheless, J. W. History of the ketogenic diet. Epilepsia 2008, 49 Suppl 8, 3-5.
72. Kossoff, E. H.; Rho, J. M. Ketogenic diets: evidence for short- and long-term efficacy. Neurotherapeutics 2009, 6, 406-414.
73. Geyelin, H. R. Fasting as a method for treating epilepsy. Med. Rec. 1921, 99, 1037-1039.
74. Putnam, T. J.; Merritt, H. H. Experimental determination of the anticonvulsant properties of some phenyl derivatives. Science 1937, 85, 525-526.
75. Merritt, H. H.; Putnam, T. J. A new series of anticonvulsant drugs tested by experiments on animals. Arch. Neurol. Psychiatry 1938, 39, 1003-1015.
76. Merritt, H. H.; Putnam, T. J. Sodium diphenyl hydantoinate in the treatment of convulsive disorders. JAMA 1938, 111, 1068-1073.
77. Richards, R. K.; Everett, G. M. Analgesic and anticonvulsant properties of 3,5,5-trimethyloxazolidine-2,4-dione (Tridione). Fed. Proc. 1944, 3, 39.
78. Lennox, W. G. The petit mal epilepsies: their treatment with Tridione. JAMA 1945, 129, 1069-1074.
79. Rogvi-Hansen, B.; Gram, L. Adverse effects of established and new antiepileptic drugs: an attempted comparison. Pharmacol. Ther. 1995, 68, 425-434.
80. Leppik, I. E. Issues in the treatment of epilepsy. Epilepsia 2001, 42 Suppl 4, 1-6.
81. Porter, R. J.; Cereghino, J. J.; Gladding, G. D.; Hessie, B. J.; Kupferberg, H. J.; Scoville, B.; White, B. G. Antiepileptic drug development program. Cleve. Clin. Q. 1984, 51, 293-305.
82. Schindler, W.; Häfliger, F. Über Derivate des Iminodibenzyls. Helvetica Chimica Acta 1954, 37, 472-483.
83. Meunier, H.; Carraz, G.; Neunier, Y.; Eymard, P.; Aimard, M. [Pharmacodynamic properties of n-dipropylacetic acid.]. Therapie 1963, 18, 435-438.
84. Perucca, E. What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate. Epilepsia 2009, 50 (Suppl. 12), 49-50.
85. Stefan, H.; Halasz, P.; Gil-Nagel, A.; Shorvon, S.; Bauer, G.; Ben Menachem, E.; Perucca, E.; Wieser, H. G.; Steinlein, O. Recent advances in the diagnosis and treatment of epilepsy. Eur. J. Neurol. 2001, 8, 519-539
86. Stacey, W. C.; Litt, B. Technology insight: neuroengineering and epilepsy-designing devices for seizure control. Nat. Clin. Pract. Neurol. 2008, 4, 190-201.
87. Shinnar, S.; Berg, A. T. Does antiepileptic drug therapy prevent the development of chronic epilepsy? Epilepsia 1996, 37, 701-708.
88. Temkin, N. R. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 2001, 42, 515-524.
89. Schachter, S. C. Current evidence indicates that antiepileptic drugs are anti-ictal, not antiepileptic. Epilepsy Res. 2002, 50, 67-70.
90. Macleod, S.; Appleton, R. E. The new antiepileptic drugs. Arch. Dis. Child Educ. Pract. Ed. 2007, 92, 182-188.
91. Marson, A. G.; Kadir, Z. A.; Hutton, J. L.; Chadwick, D. W. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997, 38, 859-880.
92. Greenwood, R. S. Adverse effects of antiepileptic drugs. Epilepsia 2000, 41 (Suppl. 2), 42-52.
93. Arroyo, S.; de la, M. A. Life-threatening adverse events of antiepileptic drugs. Epilepsy Res. 2001, 47, 155-174.
94. Eke, T.; Talbot, J. F.; Lawden, M. C. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997, 314, 180-181.
95. Hitiris, N.; Brodie, M. J. Modern antiepileptic drugs: guidelines and beyond. Curr. Opin. Neurol. 2006, 19, 175-180.
96. Bourgeois, B. F. New antiepileptic drugs. Arch. Neurol. 1998, 55, 1181-1183.
97. Brodie, M. J.; Dichter, M. A. Antiepileptic drugs. N. Engl. J. Med. 1996, 334, 168-175.
98. Schachter, S. C. Currently available antiepileptic drugs. Neurotherapeutics 2007, 4, 4-11.
99. Browne, T. R.; Penry, J. K. Benzodiazepines in the treatment of epilepsy. A review. Epilepsia 1973, 14, 277-310.
100. Sander, J. W. The use of antiepileptic drugs-principles and practice. Epilepsia 2004, 45 (Suppl. 6), 28-34.
101. Ahmed, S. N.; Siddiqi, Z. A. Antiepileptic drugs and liver disease. Seizure 2006, 15, 156-164.
102. Bjornsson, E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol. Scand. 2008, 118, 281-290.
103. Biton, V. Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003, 17, 781-791.
104. Ben Menachem, E. Weight issues for people with epilepsy-a review. Epilepsia 2007, 48 (Suppl. 9), 42-45.
105. Asconape, J. J. Some common issues in the use of antiepileptic drugs. Semin. Neurol. 2002, 22, 27-39.
106. Wilby, J.; Kainth, A.; Hawkins, N.; Epstein, D.; McIntosh, H.; McDaid, C.; Mason, A.; Golder, S.; O'Meara, S.; Sculpher, M.; Drummond, M.; Forbes, C. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol. Assess. 2005, 9, 1-4.
107. Zaccara, G.; Franciotta, D.; Perucca, E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007, 48, 1223-1244.
108. Wallace, S. J. Newer antiepileptic drugs: advantages and disadvantages. Brain Dev. 2001, 23, 277-283.
109. Van Amelsvoort, T.; Bakshi, R.; Devaux, C. B.; Schwabe, S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994, 35, 181-188.
110. Buehler, B. A.; Delimont, D.; van Waes, M.; Finnell, R. H. Prenatal prediction of risk of the fetal hydantoin syndrome. N. Engl. J. Med. 1990, 322, 1567-1572.
111. Zahn, C. Neurologic care of pregnant women with epilepsy. Epilepsia 1998, 39 (Suppl. 8), 26-31.
112. Holmes, L. B.; Harvey, E. A.; Coull, B. A.; Huntington, K. B.; Khoshbin, S.; Hayes, A. M.; Ryan, L. M. The teratogenicity of anticonvulsant drugs. N. Engl. J. Med. 2001, 344, 1132-1138.
113. Meador, K. J.; Baker, G. A.; Finnell, R. H.; Kalayjian, L. A.; Liporace, J. D.; Loring, D. W.; Mawer, G.; Pennell, P. B.; Smith, J. C.; Wolff, M. C. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006, 67, 407-412.
114. Tatum, W. O. Use of antiepileptic drugs in pregnancy. Expert. Rev. Neurother. 2006, 6, 1077-1086.
115. Kluger, B. M.; Meador, K. J. Teratogenicity of antiepileptic medications. Semin. Neurol. 2008, 28, 328-335.
116. Ikonomidou, C.; Turski, L. Antiepileptic drugs and brain development. Epilepsy Res. 2010, 88, 11-22.
117. Berkovic, S. F. Aggravation of generalized epilepsies. Epilepsia 1998, 39 (Suppl. 3), S11-S14.
118. Gayatri, N. A.; Livingston, J. H. Aggravation of epilepsy by anti-epileptic drugs. Dev. Med. Child Neurol. 2006, 48, 394-398.
119. Perucca, E.; Gram, L.; Avanzini, G.; Dulac, O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998, 39, 5-17.
120. Guerrini, R.; Belmonte, A.; Genton, P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia 1998, 39 (Suppl. 3), S2-10.
121. Tanaka, E. Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J. Clin. Pharm. Ther. 1999, 24, 87-92.
122. Leppik, I. E.; Schmidt, D. Consensus statement on compliance in epilepsy. Epilepsy Res. Suppl 1988, 1, 179-182.
123. Cramer, J. A.; Mattson, R. H.; Prevey, M. L.; Scheyer, R. D.; Ouellette, V. L. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989, 261, 3273-3277.
124. Cramer, J.; Vachon, L.; Desforges, C.; Sussman, N. M. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia 1995, 36, 1111-1117.
125. Patsalos, P. N.; Berry, D. J.; Bourgeois, B. F.; Cloyd, J. C.; Glauser, T. A.; Johannessen, S. I.; Leppik, I. E.; Tomson, T.; Perucca, E. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008, 49, 1239-1276.
126. Onat, F.; Ozkara, C. Adverse effects of new antiepileptic drugs. Drugs Today (Barc.) 2004, 40, 325-342.
127. Sabers, A.; Gram, L. Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs 2000, 60, 23-33.
128. Lalonde, R. L.; Kowalski, K. G.; Hutmacher, M. M.; Ewy, W.; Nichols, D. J.; Milligan, P. A.; Corrigan, B. W.; Lockwood, P. A.; Marshall, S. A.; Benincosa, L. J.; Tensfeldt, T. G.; Parivar, K.; Amantea, M.; Glue, P.; Koide, H.; Miller, R. Model-based drug development. Clin. Pharmacol. Ther. 2007, 82, 21-32.
129. Pennell, P. B.; Ogaily, M. S.; Macdonald, R. L. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology 1995, 45, 456-460.
130. O'Neil, M. G.; Perdun, C. S.; Wilson, M. B.; McGown, S. T.; Patel, S. Felbamate-associated fatal acute hepatic necrosis. Neurology 1996, 46, 1457-1459.
131. White, H. S. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia 1997, 38 (Suppl. 1), S9-17.
132. Everett, G. M.; Richards, R. K. Comparative anticonvulsive action of 3,5,5-trimethyloxazolidine-2,4-dione (tridione), dilantin, and phenobarbital. J. Pharmacol. Exp. Ther. 1944, 81, 402-407.
133. Swinyard, E. A. Laboratory evaluation of antiepileptic drugs. Review of laboratory methods. Epilepsia 1969, 10, 107-119.
134. Krall, R. L.; Penry, J. K.; White, B. G.; Kupferberg, H. J.; Swinyard, E. A. Antiepileptic Drug Development: II. Anticonvulsant Drug Screening. Epilepsia 1978, 19, 409-428.
135. White, H. S. Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia 2003, 44 (Suppl. 7), 2-8.
136. Smith, M.; Wilcox, K. S.; White, H. S. Discovery of antiepileptic drugs. Neurotherapeutics 2007, 4, 12-17.
137. Miller, A. A.; Wheatley, P.; Sawyer, D. A.; Baxter, M. G.; Roth, B. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats. Epilepsia 1986, 27, 483-489.
138. Ferrie, C. D.; Robinson, R. O.; Knott, C.; Panayiotopoulos, C. P. Lamotrigine as an add-on drug in typical absence seizures. Acta Neurol. Scand. 1995, 91, 200-202.
139. Glauser, T. A.; Cnaan, A.; Shinnar, S.; Hirtz, D. G.; Dlugos, D.; Masur, D.; Clark, P. O.; Capparelli, E. V.; Adamson, P. C. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N. Engl. J. Med. 2010, 362, 790-799.
140. Gower, A. J.; Noyer, M.; Verloes, R.; Gobert, J.; Wulfert, E. UCB L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur. J. Pharmacol. 1992, 222, 193-203.
141. Gower, A. J.; Hirsch, E.; Boehrer, A.; Noyer, M.; Marescaux, C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 1995, 22, 207-213.
142. Klitgaard, H.; Matagne, A.; Gobert, J.; Wulfert, E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 1998, 353, 191-206.
143. Leschinger, A.; Stabel, J.; Igelmund, P.; Heinemann, U. Pharmacological and electrographic properties of epileptiform activity induced by elevated K+ and lowered Ca2+ and Mg2+ concentration in rat hippocampal slices. Exp. Brain Res. 1993, 96, 230-240.
144. Yaari, Y.; Konnerth, A.; Heinemann, U. Spontaneous epileptiform activity of ca1 hippocampal neurons in low extracellular calcium solutions. Exp. Brain Res. 1983, 51, 153-156.
145. Mody, I.; Lambert, J. D.; Heinemann, U. Low extracellular magnesium induces epileptiform activity and spreading depression in rat hippocampal slices. J. Neurophysiol. 1987, 57, 869-888.
146. Fueta, Y.; Avoli, M. Effects of antiepileptic drugs on 4-aminopyridine-induced epileptiform activity in young and adult rat hippocampus. Epilepsy Res. 1992, 12, 207-215.
147. Bruckner, C.; Heinemann, U. Effects of standard anticonvulsant drugs on different patterns of epileptiform discharges induced by 4-aminopyridine in combined entorhinal cortex-hippocampal slices. Brain Res. 2000, 859, 15-20.
148. Stasheff, S. F.; Bragdon, A. C.; Wilson, W. A. Induction of epileptiform activity in hippocampal slices by trains of electrical stimuli. Brain Res. 1985, 344, 296-302.
149. Higashima, M.; Kinoshita, H.; Yamaguchi, N.; Koshino, Y. Activation of gabaergic function necessary for afterdischarge generation in rat hippocampal slices. Neurosci. Lett. 1996, 207, 101-104.
150. Isomura, Y.; Fujiwara-Tsukamoto, Y.; Takada, M. A network mechanism underlying hippocampal seizure-like synchronous oscillation. Neurosci. Res. 2008, 61, 227-233.
151. Wahab, A.; Albus, K.; Heinemann, U. Drug refractoriness of epileptiform activity in organotypic hippocampal slice cultures depends on the mode of provocation. Epilepsy Res. 2010, in press.
152. Loscher, W.; Rundfeldt, C.; Honack, D. Pharmacological characterization of phenytoin-resistant amygdala-kindled rats, a new model of drug-resistant partial epilepsy. Epilepsy Res. 1993, 15, 207-219.
153. Postma, T.; Krupp, E.; Li, X. L.; Post, R. M.; Weiss, S. R. Lamotrigine treatment during amygdala-kindled seizure development fails to inhibit seizures and diminishes subsequent anticonvulsant efficacy. Epilepsia 2000, 41, 1514-1521.
154. Brown, W. C.; Schiffman, D. O.; Swinyard, E. A.; Goodman, L. S. Comparative assay of an antiepileptic drugs by psychomotor seizure test and minimal electroshock threshold test. J. Pharmacol. Exp. Ther. 1953, 107, 273-283.
155. Barton, M. E.; Klein, B. D.; Wolf, H. H.; White, H. S. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 2001, 47, 217-227.
156. Leite, J. P.; Cavalheiro, E. A. Effects of conventional antiepileptic drugs in a model of spontaneous recurrent seizures in rats. Epilepsy Res. 1995, 20, 93-104.
157. Grabenstatter, H. L.; Ferraro, D. J.; Williams, P. A.; Chapman, P. L.; Dudek, F. E. Use of chronic epilepsy models in antiepileptic drug discovery: the effect of topiramate on spontaneous motor seizures in rats with kainate-induced epilepsy. Epilepsia 2005, 46, 8-14.
158. van Vliet, E. A.; van Schaik, R.; Edelbroek, P. M.; Redeker, S.; Aronica, E.; Wadman, W. J.; Marchi, N.; Vezzani, A.; Gorter, J. A. Inhibition of the multidrug transporter p-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 2006, 47, 672-680.
159. Smyth, M. D.; Barbaro, N. M.; Baraban, S. C. Effects of antiepileptic drugs on induced epileptiform activity in a rat model of dysplasia. Epilepsy Res. 2002, 50, 251-264.
160. Brückner, C.; Stenkamp, K.; Meierkord, H.; Heinemann, U. Epileptiform discharges induced by combined application of bicuculline and 4-aminopyridine are resistant to standard anticonvulsants in slices of rats. Neurosci. Lett. 1999, 268, 163-165.
161. Dreier, J. P.; Heinemann, U. Late low magnesium-induced epileptiform activity in rat entorhinal cortex slices becomes insensitive to the anticonvulsant valproic acid. Neurosci. Lett. 1990, 119, 68-70.
162. Zhang, C. L.; Dreier, J. P.; Heinemann, U. Paroxysmal epileptiform discharges in temporal lobe slices after prolonged exposure to low magnesium are resistant to clinically used anticonvulsants. Epilepsy Res. 1995, 20, 105-111.
163. Albus, K.; Wahab, A.; Heinemann, U. Standard antiepileptic drugs fail to block epileptiform activity in rat organotypic hippocampal slice cultures. Br. J. Pharm. 2008, 154, 709-724.
164. Wahab, A.; Heinemann, U.; Albus, K. Effects of gamma-aminobutyric acid (GABA) agonists and a GABA uptake inhibitor on pharmacoresistant seizure like events in organotypic hippocampal slice cultures. Epilepsy Res. 2009, 86, 113-123.
165. Quilichini, P. P.; Diabira, D.; Chiron, C.; Milh, M.; Ben Ari, Y.; Gozlan, H. Effects of antiepileptic drugs on refractory seizures in the intact immature corticohippocampal formation in vitro. Epilepsia 2003, 44, 1365-1374.
166. Wozny, C.; Kivi, A.; Lehmann, T. N.; Dehnicke, C.; Heinemann, U.; Behr, J. Comment on on the origin of interictal activity in human temporal lobe epilepsy in vitro. Science 2003, 301, 463.
167. Remy, S.; Gabriel, S.; Urban, B. W.; Dietrich, D.; Lehmann, T. N.; Elger, C. E.; Heinemann, U.; Beck, H. A novel mechanism underlying drug resistance in chronic epilepsy. Ann. Neurol. 2003, 53, 469-479.
168. Gabriel, S.; Njunting, M.; Pomper, J. K.; Merschhemke, M.; Sanabria, E. R.; Eilers, A.; Kivi, A.; Zeller, M.; Meencke, H. J.; Cavalheiro, E. A.; Heinemann, U.; Lehmann, T. N. Stimulus and potassium-induced epileptiform activity in the human dentate gyrus from patients with and without hippocampal sclerosis. J. Neurosci. 2004, 24, 10416-10430.
169. Jandova, K.; Pasler, D.; Antonio, L. L.; Raue, C.; Ji, S.; Njunting, M.; Kann, O.; Kovacs, R.; Meencke, H. J.; Cavalheiro, E. A.; Heinemann, U.; Gabriel, S.; Lehmann, T. N. Carbamazepine-resistance in the epileptic dentate gyrus of human hippocampal slices. Brain 2006, 129, 3290-3306.
170. Oby, E.; Caccia, S.; Vezzani, A.; Moeddel, G.; Hallene, K.; Guiso, G.; Said, T.; Bingaman, W.; Marchi, N.; Baumgartner, C.; Pirker, S.; Czech, T.; Lo, R. G.; Janigro, D. In vitro responsiveness of human-drug-resistant tissue to antiepileptic drugs: insights into the mechanisms of pharmacoresistance. Brain Res. 2006, 1086, 201-213.
171. Snead, O. C. 3rd. Pharmacological models of generalized absence seizures in rodents. J. Neural Transm. Suppl. 1992, 35, 7-19.
172. Jefferys, J. G. Models and mechanisms of experimental epilepsies. Epilepsia 2003, 44 (Suppl. 12), 44-50.
173. McNamara, J. O. Development of new pharmacological agents for epilepsy: lessons from the kindling model. Epilepsia 1989, 30 (Suppl. 1), 13-18.
174. Turski, W. A.; Cavalheiro, E. A.; Bortolotto, Z. A.; Mello, L. M.; Schwarz, M.; Turski, L. Seizures produced by pilocarpine in mice: a behavioral, electroencephalographic and morphological analysis. Brain Res. 1984, 321, 237-253.
175. Cavalheiro, E. A.; Leite, J. P.; Bortolotto, Z. A.; Turski, W. A.; Ikonomidou, C.; Turski, L. Long-term effects of pilocarpine in rats: structural damage of the brain triggers kindling and spontaneous recurrent seizures. Epilepsia 1991, 32, 778-782.
176. Sharma, A. K.; Reams, R. Y.; Jordan, W. H.; Miller, M. A.; Thacker, H. L.; Snyder, P. W. Mesial temporal lobe epilepsy: pathogenesis, induced rodent models and lesions. Toxicol. Pathol. 2007, 35, 984-999.
177. Curia, G.; Longo, D.; Biagini, G.; Jones, R. S.; Avoli, M. The pilocarpine model of temporal lobe epilepsy. J. Neurosci. Methods 2008, 172, 143-157.
178. Johannessen, L. C.; Johannessen, S. I. Pharmacological management of epilepsy: recent advances and future prospects. Drugs 2008, 68, 1925-1939.
179. Johannessen, L. C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008, 22, 27-47.
180. Perucca, E. An introduction to antiepileptic drugs. Epilepsia 2005, 46 (Suppl. 4), 31-37.
181. Wetter, T. C.; Winkelmann, J.; Eisensehr, I. Current treatment options for restless legs syndrome. Expert. Opin. Pharmacother. 2003, 4, 1727-1738.
182. Lejoyeux, M.; Solomon, J.; Ades, J. Benzodiazepine treatment for alcohol-dependent patients. Alcohol Alcohol 1998, 33, 563-575.
183. Dworkin, R. H.; O'Connor, A. B.; Audette, J.; Baron, R.; Gourlay, G. K.; Haanpaa, M. L.; Kent, J. L.; Krane, E. J.; Lebel, A. A.; Levy, R. M.; Mackey, S. C.; Mayer, J.; Miaskowski, C.; Raja, S. N.; Rice, A. S.; Schmader, K. E.; Stacey, B.; Stanos, S.; Treede, R. D.; Turk, D. C.; Walco, G. A.; Wells, C. D. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin. Proc. 2010, 85, S3-14.
184. Pappagallo, M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin. Ther. 2003, 25, 2506-2538.
185. Evins, A. E. Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J. Clin. Psychiatry 2003, 64 Suppl 8, 9-14.
186. Keck, P. E., Jr.; Strawn, J. R.; McElroy, S. L. Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders. J. Clin. Psychiatry 2006, 67 (Suppl. 1), 8-15.
187. Vikelis, M.; Rapoport, A. M. Role of antiepileptic drugs as preventive agents for migraine. CNS Drugs 2010, 24, 21-33.